SCHEMBL6076353

SCHEMBL6076353

Clc1ccc(-c2nc(Cl)c3c(n2)CCCC3)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HPGD P15428 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
EEF2K O00418 1/20 0.42
ACHE P22303 7/20 0.42
AHR P35869 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
BCHE P06276 5/20 0.37
HRH4 Q9H3N8 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CHRM1 P11229 1/20 0.37
EPHX2 P34913 1/20 0.37
LMNA P02545 1/20 0.37
GRIN1 Q05586 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076618 0.85 NPC1 (0.45) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL16179662 0.83 MAPK1 (0.47) HPGDALDH1A1MAPTNPSR1ACHE
SCHEMBL6075340 0.82 TP53 (0.48) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL16179999 0.80 TP53 (0.47) NPC1HPGDALDH1A1MAPTACHE
SCHEMBL6076679 0.80 KDM4E (0.49) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL6076716 0.80 MAPK1 (0.55) HPGDMAPTACHEMEN1KMT2A
SCHEMBL7500873 0.79 KDM4E (0.45) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL6076028 0.79 KDM4E (0.47) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL6075498 0.79 PDE5A (0.41) NPC1RAB9AEEF2KMEN1KMT2A
SCHEMBL6075978 0.79 ACHE (0.42) ACHEBCHECHRM1EPHX2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045526-B2 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-05-16 US disclosed
US-20040063690-A1 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-04-01 US disclosed
US-6660746-B1 Cardiovascular disorders AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-12-09 US disclosed
EP-1150963-B1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AVENTIS PHARMA GMBH (DE) 2003-12-03 EP disclosed
EP-1150963-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2001-11-07 EP disclosed
WO-2000046214-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063690-A1 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them PDE3A, PDE2A, PDE3B NPC1 1260/4885RAB9A 1596/4885HPGD 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.